Administration of cyclophosphamide changes the immune profile of tumor-bearing mice

Journal of Immunotherapy

Volumn 33, Issue 1, 2010, Pages 53-59

  Liu, Pu ^a   Jaffar, Jade ^a   Hellstrom, Ingegerd ^a   Hellstrom, Karl Erik ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cyclophosphamide; MDSC; TIL; Treg

Indexed keywords

B7 ANTIGEN; CD11B ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; CELL MARKER; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; GLYCOPROTEIN P 15095; INTERLEUKIN 2 RECEPTOR ALPHA; PROTEIN GR1; PROTEIN NK1.1; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CANCER IMMUNIZATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFECT; FEMALE; LYMPHOID CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; TUMOR; TUMOR ASSOCIATED LEUKOCYTE; TUMOR REJECTION;

ANIMALS; B-LYMPHOCYTES; CANCER VACCINES; CELL SEPARATION; CYCLOPHOSPHAMIDE; FEMALE; FLOW CYTOMETRY; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTE SUBSETS;

EID: 74349102406     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181b56af4     Document Type: Article

References (34)

1. Boon T, Coulie PG, Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today. 1997;18:267-268.
2. Old LJ, Chen YT. New paths in human cancer serology. J Exp Med. 1998;187:1163-1167.
3. Prehn R, Main D. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst. 1957;18:769-778.
4. Malins DC, Anderson KM, Gilman NK, et al. Development of a cancer DNA phenotype prior to tumor formation. Proc Natl Acad Sci. 2004;101:10721-10725.
5. Bielas JH, Loeb KR, Rubin BP, et al. Human cancers express a mutator phenotype. Proc Natl Acad Sci. 2006;103:18238-18242.
6. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909-915.
7. Hellstrom KE, Hellstrom I, Kant JA, et al. Regression and inhibition of sarcoma growth by interference with a radiosensitive T cell population. J Exp Med. 1978;148:799-804.
8. Mule' J, Jones FR, Hellstrom I, et al. Selective localization of radiolabelled immune lymphocytes into syngeneic tumors. J Immunol. 1979;123:600-606.
9. North RJ. Radiation-induced, immunologically mediated regression of an established tumor as an example of successful therapeutic immunomanipulation. Preferential elimination of suppressor T cells allows sustained production of effector T cells. J Exp Med. 1986;164:1652-1666.
10. North RJ. Down-regulation of the antitumor immune response. Adv Cancer Res. 1985;45:1-43.
11. +, 2-T cells. Tumor eradication does not require participation of cytotoxic T cells. J Exp Med 1985;161:1122-1134.
12. Estin CD, Stevenson US, Hellstrom I, et al. Cyclophosphamide potentiates the antitumor activity of v-p97NY. Cell Immunol. 1989;120:126-131.
13. Turk MJ, Guevara-Patino JA, Rizzuto GA, et al. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med. 2004;200:771-782.
14. Di Paolo NC, Tuve S, Ni S, et al. Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses. Cancer Res. 2006;66:960-969.
15. Yang Y, Yang S, Ye Z, et al. Tumor cells expressing anti-CD137 scFv induce a tumor-destructive environment. Cancer Res. 2007;67:2339-2344.
16. Liu P, Jaffar J, Zhou J, et al. Inhibition of TGFbeta 1 makes nonimmunogenic tumor cells effective for therapeutic vaccination. J Immunother. 2009;32:232-239.
17. Brode S, Cooke A. Immune-potentiating effects of the chemo-therapeutic drug cyclophosphamide. Crit Rev Immunol. 2008; 28:109-126.
18. Yang SC, Yang Y, Raycraft J, et al. Melanoma cells trans-fected to express CD83 induce anti-tumor immunity that can be increased by also engaging CD137. Proc Natl Acad Sci. 2004;101:4990-4995.
19. Mihich E. Modulation of antitumor immune responses. Cancer Detect Prev Suppl. 1987;1:399-407.
20. Prendergast GC, Jaffee EM. Cancer immunologists and cancer biologists: why we didn't talk then but need to now. Cancer Res. 2007;67:3500-3504.
21. Price JE, Tarin D, Fidler I. Influence of organ microenviron-ment on pigmentation of a metastatic murine melanoma. Cancer Res. 1988;48:2258-2264.
22. Uchida J, Lee Y, Hasegawa M, et al. Mouse CD20 expression and function. Int Immunol. 2004;16:119-129.
23. Ferrero I, Held W, Wilson A, et al. Mouse CD11c(+) B220(+)Gr1(+) plasmacytoid dendritic cells develop independently of the T cell lineage. Blood. 2002;100:2852-2857.
24. + myeloid-derived suppressor cells from the bone marrow. Cancer Res. 2009;69:3554-3562.
25. Vremec D, Shortman K. Dendritic cell subtypes in mouse lymphoid organs: cross-correlation of surface markers, changes with incubation, and differences among thymus, spleen and lymph nodes. J Immunol. 1997;159:565-573.
26. Rudensky AY, Gavin MA, Zheng Y. FOXP3 and NFAT:-partners in tolerance. Cell. 2006;126:253-256.
27. + T regulatory cells. Nat Immunol. 2003; 4:337-342.
28. Clarka CE, Beattya GL, Vonderheide RH. Immunosurveill-ance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer. Cancer Letters. 2009; 279:1-7.
29. Angulo I, de las Heras F, Garcia-Bustos J, et al. Nitric oxide-producing CD11b(+) Ly-6G(Gr-1)(+) CD31(ER-MP12)(+) cells in the spleen of cyclophosphamide-treated mice: implications for T cell responses in immunosuppressed mice. Blood. 2000;95:212-220.
30. Diaz-Montero CM, Salem M, Nishimura MI, et al. Increased circulating myeloid-derived suppressor cells correlate with clinical stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immun-other. 2009;58:49-59.
31. Ye Z, Hellstrom I, Hayden-Ledbetter M, et al. Gene therapy for cancer using sjingle-chain Fv fragments specific for 4-1BB. Nat Med. 2002;8:343-348.
32. Hellstrom KE, Hellstrom I. Enhancement of tumor outgrowth by tumor-associated blocking factors. Int J Cancer. 1979;23: 366-373.
33. Zhang Y, Pastan I. High shed antigen levels within tumors: an additional barrier to immunoconjugate therapy. Clin Cancer Res. 2008;14:7981-7986.
34. Hellstromn KE, Hellstrom I. Vaccines to trat cancer-an old approach with new possibilities. J Cell Biochem. 2007;102: 291-300.